Pfizer, Protalix get pediatric OK for Gaucher drug Elelyso; South Africa's Aspen sees earnings rise;

@FiercePharma: Top-read on FierceVaccines yesterday: Does Pfizer still need AstraZeneca's vaccines business? Story | Follow @FiercePharma

@EricPFierce: CPhI Worldwide will host #CPhIChat to debate the future of pharma for those of you who want a piece of that. Release | Follow @EricPFierce

@CarlyHFierce: Pfizer's C. diff vaccine gains on Sanofi with FDA fast-track nod. Story | Follow @CarlyHFierce

> Pfizer ($PFE) and Protalix BioTherapeutics ($PLX) have won FDA approval for pediatric use of Elelyso for long-term enzyme replacement therapy for Type 1 Gaucher disease. Release

> Sources say Johnson & Johnson ($JNJ) is looking for buyers for stentmaking Cordis unit. Story

> Japan's Otsuka Pharmaceutical has struck a deal to buy Brazilian health food group Jasmine Alimentos. Story

> Daiichi Sankyo said it has a deal to sell in Japan, the hepatitis B vaccine Bimmugen, which was developed by The Chemo-Sero-Therapeutic Research Institute. Announcement

Medical Device News

@FierceMedDev: New imaging system uses biomarker to guide brain cancer surgery. More | Follow @FierceMedDev

@VarunSaxena2: Between new Brain project initiative and 2 recent $COV buys + $BSX's buy of Bayer's devices, peripheral devices are officially a thing. | Follow @VarunSaxena2

@MichaelGFierce: Organic nanoparticles offer 'complete package' against cancer: delivery and imaging. Article | Follow @MichaelGFierce

> Bayer's startup accelerator funds five device, healthcare app companies. Story

> Covidien acquires Sapheon ahead of FDA approval for vein adhesive. More

Biotech News

@FierceBiotech: Band of West Coast biotech insiders pushes oral anticoagulant to PhIII. Article | Follow @FierceBiotech

@JohnCFierce: The EuroBiotech report: Ex-Shire exec starts at Cortendo, Innate gets orphan nod, Ablynx trims in preclinical. Story | Follow @JohnCFierce

@EmilyMFierce: Canadian Immunovaccine reports positive preclinical data for Ebola vaccine. More | Follow @EmilyMFierce

> ThromboGenics spins out cancer R&D, scales down staff amid lackluster Jetrea sales. Article

> Booming Gilead blueprints an overhaul of its campus. Item

And Finally... South Africa's Aspen Pharmacare reported that earnings per share excluding one-time items rose 26% for its year ended June 30. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.